CHRONIC KIDNEY DISEASE AND CHRONIC HEART FAILURE: IMPACT ON PROGNOSIS OF THERAPY

Authors

  • Khasanova M. A. Tashkent medical academy
  • Umarova Z. F. Tashkent medical academy
  • Kodirova Sh. A. Tashkent medical academy
  • Khodjanova Sh. I. Tashkent medical academy
  • Ismailova G. A. Tashkent medical academy
  • Rakhmatov A. M. Tashkent medical academy
  • Jumanazarov S.B. Tashkent medical academy

Keywords:

heart failure, chronic kidney disease, registry, prognosis, treatment

Abstract

Background. Chronic heart failure (CHF) is a serious problem of modern healthcare, being a consumer of significant material resources due to high frequency of hospitalisation and unfavourable prognosis. CHF quite often coexists with a number of comorbidities, among which chronic kidney disease (CKD) is of particular importance

Objective. To evaluate the impact of decreased glomerular filtration rate (GFR) on the prognosis of patients with chronic heart failure (CHF), to analyse clinical practice with regard to the frequency of prescription of pathogenetic therapy for CHF, achievement of target doses depending on the gradation of GFR in patients.

Materials and Methods. Medical data of 102 patients (40 men and 62 women) with CHF of I-IV functional class NYHA were included in the analysis. Inclusion criteria in the register: proven CHF. Chronic kidney disease was assessed by (GFR) calculated by the CKD-EPI formula (ml/min/1.73 m2). The primary endpoint was defined as all-cause death.

Results. (GFR)<60 ml/min/1.73 m2 was registered in 31.2% of patients, more frequently in women (39 and 28.8%, respectively; p<0.001). When dividing patients into phenotypes according to left ventricular ejection fraction (LVEF), no statistically significant differences were found in the distribution of patients according to(GFR). In patients with CHF with low LVEF (HFlEF) and CHF with preserved LVEF (HFpEF), an GFR<45 ml/min/1.73 m2 was associated with an increased risk of endpoints. Analysis of the prescribed pathogenetic therapy showed that in patients with HFlFV the frequency of prescription of angiotensin-converting enzyme inhibitors (ACEIs), β-adrenoblockers and mineralocorticoid receptor antagonists (MCRAs) decreased (p=0.024, 0.007 and 0.01 respectively), while angiotensin receptor and neprilysin inhibitor increased with decreasing(GFR) (p=0.027). In patients with CHFV, a similar trend of decreasing frequency of prescription of IAPPs and MCRAs with decreasing CRP (p<0.001) persisted, but it was compensated by an inversely proportional increase in the frequency of prescription of angiotensin receptor blockers (p<0.001). One hundred per cent of the target dosage was achieved by more than 85% of patients taking AMKR across the entire range of LVEF, whereas for β-adrenoblockers and angiotensin receptor and neprilysin inhibitor/IAPP/angiotensin receptor blockers the percentage of patients receiving the full therapeutic dosage of the drugs was significantly lower. When analysing target doses of pathogenic drugs, the gradations of achieved doses were evenly distributed throughout the entire range of(GFR).

Conclusion. (GFR)<60 ml/min/1.73 m2 occurs in every 3rd patient with CHF in the whole range of LVEF. Decreased(GFR) worsens the prognosis of patients with both CHFlFV and CHFpFV, increasing in direct proportion with the severity of the stage of chronic kidney disease. Inclusion of patients in the surveillance programme within the framework of the CHF service makes it possible to significantly approach the current treatment to the optimal drug therapy, at the same time, certain efforts are required to overcome the difficulties with titration to target dosages.

References

1. Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610-23. DOI:10.1038/nrneph.2016.113

2. Nicolas J, Claessen B, Mehran R. Implications of Kidney Disease in the Cardiac Patient. IntCardiolClin. 2020;9(3):265-78. DOI:10.1016/j.iccl.2020.03.002

3. Ruocco G, Palazzuoli A, terMaaten JM. The role of the kidney in acute and chronic heart failure. Heart Fail Rev. 2020;25(1):107-18. DOI:10.1007/s10741-019-09870-6

4. Beldhuis IE, Lam CSP, Testani JM, et al. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation. 2022;145(9):693-712. DOI:10.1161/CIRCULATIONAHA.121.052792

5. Li X, Lindholm B. Cardiovascular Risk Prediction in Chronic Kidney Disease. Am J Nephrol. 2022;53(10):730-9. DOI:10.1159/000528560

6. Pontremoli R, Borghi C, PerroneFilardi P. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J CardiovascPharmacother. 2021;7(5):445-52. DOI:10.1093/ehjcvp/pvab030

7. Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31. DOI:10.1016/S2213-8587(20)30369-7

8. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. New Engl J Med. 2023;388(2):117-27. DOI:10.1056/NEJMoa2204233

9. Banerjee D, Rosano G, Herzog CA. Management of heart failure patient with CKD. Clin J Am SocNephrol. 2021;16(7):1131-9. DOI:10.2215/CJN.14180920

10. Wetmore JB, Yan H, Horne L, et al. Risk of hyperkalemia from reninangiotensin-aldosterone system inhibitors and factors associated with treatment discontinuations in a real-world population. Nephrol Dial Transplant. 2021;36(5):826-39. DOI:10.1093/ndt/gfz263

11. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368

12. Kobalava J.D., Conradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical recommendations 2020. Russian Journal of Cardiology. 2020;25(3):3786 [KobalavaZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (in Russian)]. DOI:10.15829/1560-4071-2020-3-3786

13. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. DOI:10.7326/0003-4819-150-9-200905050-00006

14. Dedov I.I., Mokrysheva N.G., Melnichenko G.A., et al. Obesity. Clinical recommendations. ConsiliumMedicum. 2021;23(4):311-25 [Dedov II, Mokrysheva NG, Mel'nichenko GA, et al. Obesity. Clinical guidelines. ConsiliumMedicum. 2021;23(4):311-25 (in Russian)]. DOI:10.26442/20751753.2021.4.200832

15. Fomin I.V. Chronic heart failure in the Russian Federation: what today we know and what we should do. Russian cardiological journal. 2016;(8):7-13 [Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13 (in Russian)]. DOI:10.15829/1560-4071-2016-8-7-13

16. Khadzegova A.B. Renal function in heart failure - a predictor of the choice of RAAS blockers. RMZ. Medical Review. 2023;7(1):30-5 [Khadzegova AB. Renal function in patients with heart failure - a predictor for selecting RAAS inhibitors. Russian Medical Inquiry. 2023;7(1):30-5 (in Russian)]. DOI:10.32364/2587-6821-2023-7-1-30-35

17. Lawson CA, Zaccardi F, Squire I, et al. Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. Circ Heart Fail. 2020;13(2):e006472. DOI:10.1161/CIRCHEARTFAILURE.119.006472

18. Shlyakhto E.V., Belenkov Y.N., Boitsov S.A., et al. Results of interim analysis of the prospective observational multicentre registry study of patients with chronic heart failure in the Russian Federation 'PRIORITY-CHF': baseline characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):5593 [Shlyakhto EV, BelenkovYuN, Boytsov SA, et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation "PRIORITET-CHF": initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):5593 (in Russian)]. DOI:10.15829/1560-4071-2023-5593

19. Khan MS, SammanTahhan A, Vaduganathan M, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail. 2020;22(6):1032-42. DOI:10.1002/ejhf.1818

20. Löfman I, Szummer K, Hagerman I, et al. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3(1):e000324. DOI:10.1136/openhrt-2015-000324

21. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190

22. Polyakov D.S., Fomin I.V., Belenkov Y.N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of observation? Results of the EPOHA-CHF study. Cardiology. 2021;61(4):4-14 [Polyakov DS, Fomin IV, BelenkovYuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian)]. DOI:10.18087/cardio.2021.4.n1628

23. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am CollCardiol. 2018;72(4):351-66. DOI:10.1016/j.jacc.2018.04.070

24. Komajda M, Anker SD, Cowie MR, et al. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514-22. DOI:10.1002/ejhf.510

25. Fomin I.V., Polyakov D.S., Vaisberg A.R. 25 years of real clinical practice in the treatment of chronic heart failure in the Russian Federation - are we doing everything right in 2022? Medical Almanac. 2022;4(73):27-37 [Fomin IV, Polyakov DS, Vaisberg AR. 25 years of chronic heart failure treatment in clinical practice in the Russian Federation - are we doing everything right in 2022. MeditsinskiiAlmanakh. 2022;4(73):27-37 (in Russian)].

Downloads

Published

2024-11-26

How to Cite

M. A., K., Z. F., U., Sh. A., K., Sh. I., K., G. A., I., A. M., R., & S.B., J. (2024). CHRONIC KIDNEY DISEASE AND CHRONIC HEART FAILURE: IMPACT ON PROGNOSIS OF THERAPY. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 4(11), 632–637. Retrieved from http://inovatus.es/index.php/ejmmp/article/view/4583

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.